{"id":"paricalcitol-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Elevated calcium-phosphate product"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paricalcitol binds to and activates the vitamin D receptor (VDR), a nuclear receptor that regulates gene expression involved in calcium homeostasis, phosphate metabolism, and parathyroid hormone (PTH) suppression. By selectively activating VDR with greater specificity for parathyroid tissue compared to intestinal and bone tissue, paricalcitol reduces PTH levels while minimizing hypercalcemia and hyperphosphatemia that can occur with less selective vitamin D analogs.","oneSentence":"Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:52.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis"},{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 not on dialysis"}]},"trialDetails":[{"nctId":"NCT05664880","phase":"EARLY_PHASE1","title":"A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2023-06-01","conditions":"Chronic Pancreatitis","enrollment":24},{"nctId":"NCT02876211","phase":"PHASE4","title":"Paricalcitol Improves Anemia of Inflammation","status":"TERMINATED","sponsor":"Hospital Son Espases","startDate":"2014-12","conditions":"Anemia","enrollment":19},{"nctId":"NCT03588884","phase":"PHASE4","title":"Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2018-06-08","conditions":"Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3","enrollment":69},{"nctId":"NCT04994080","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism","status":"UNKNOWN","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2022-02-01","conditions":"Secondary Hyperparathyroidism","enrollment":84},{"nctId":"NCT02018133","phase":"","title":"Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2009-12","conditions":"CKD Stage 3/4","enrollment":8},{"nctId":"NCT00417612","phase":"PHASE3","title":"Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-01","conditions":"Hypophosphatemia, Familial, Hyperparathyroidism","enrollment":33},{"nctId":"NCT01939977","phase":"PHASE4","title":"Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.","status":"COMPLETED","sponsor":"Fundación Senefro","startDate":"2014-01","conditions":"Secondary Hyperparathyroidism Due to Renal Causes","enrollment":148},{"nctId":"NCT00634582","phase":"PHASE2","title":"Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2009-01","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":2},{"nctId":"NCT01020487","phase":"PHASE3","title":"Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Chronic Kidney Disease Stage 3 and 4","enrollment":47},{"nctId":"NCT01382212","phase":"PHASE3","title":"A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"End-Stage Renal Disease, Secondary Hyperparathyroidism","enrollment":13},{"nctId":"NCT00752102","phase":"PHASE4","title":"Vitamin D and Coronary Calcification Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2008-09","conditions":"Chronic Kidney Disease, Vitamin D Deficiency, Coronary Calcification","enrollment":44},{"nctId":"NCT01138475","phase":"PHASE3","title":"Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery","status":"COMPLETED","sponsor":"Kerstyn C. Zalesin, M.D.","startDate":"2010-07","conditions":"Gastric Bypass, Parathyroid Hormone","enrollment":49},{"nctId":"NCT00796679","phase":"NA","title":"Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2008-10","conditions":"Chronic Kidney Disease","enrollment":60},{"nctId":"NCT02282813","phase":"PHASE3","title":"Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2013-04","conditions":"Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency","enrollment":298},{"nctId":"NCT01265615","phase":"PHASE4","title":"Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients","status":"COMPLETED","sponsor":"Ural State Medical University","startDate":"2009-10","conditions":"Cardiorenal Syndrome, Chronic Allograft Nephropathy","enrollment":109},{"nctId":"NCT00463021","phase":"PHASE4","title":"A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-04","conditions":"Secondary Hyperparathyroidism","enrollment":36},{"nctId":"NCT02322632","phase":"PHASE1","title":"Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-11","conditions":"Healthy","enrollment":69},{"nctId":"NCT01083849","phase":"","title":"Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-03","conditions":"Kidney Insufficiency, Secondary Hyperparathyroidism","enrollment":761},{"nctId":"NCT01224782","phase":"","title":"Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Chronic Kidney Disease, Secondary Hyperparathyroidism","enrollment":994},{"nctId":"NCT01265992","phase":"","title":"Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-02","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":50},{"nctId":"NCT01630408","phase":"NA","title":"The Effects of Active VItamin D on Left Atrial Volume Index","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-03","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT01134315","phase":"","title":"Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice","status":"TERMINATED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-06","conditions":"Secondary Hyperparathyroidism, End-Stage Renal Disease","enrollment":61},{"nctId":"NCT00587158","phase":"NA","title":"Oral Paricalcitol in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary","enrollment":100},{"nctId":"NCT00497146","phase":"PHASE3","title":"The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-02","conditions":"Chronic Kidney Disease, Left Ventricular Hypertrophy","enrollment":227},{"nctId":"NCT01220050","phase":"PHASE2","title":"Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2009-09","conditions":"Renal Transplant, Secondary Hyperparathyroidism","enrollment":43},{"nctId":"NCT01680198","phase":"PHASE3","title":"Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)","status":"COMPLETED","sponsor":"Fondazione C.N.R./Regione Toscana \"G. Monasterio\", Pisa, Italy","startDate":"2011-06","conditions":"Chronic Kidney Disease.","enrollment":88},{"nctId":"NCT00977080","phase":"PHASE4","title":"Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-11","conditions":"Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis","enrollment":272},{"nctId":"NCT01442272","phase":"PHASE4","title":"Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D","status":"UNKNOWN","sponsor":"Hospital Universitario de Canarias","startDate":"2012-01","conditions":"Kidney Failure, Chronic, Disorder of Vitamin D","enrollment":174},{"nctId":"NCT01331317","phase":"PHASE4","title":"Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy","status":"COMPLETED","sponsor":"Peter Rossing","startDate":"2010-04","conditions":"Cardiovascular Disease, Diabetic Nephropathy","enrollment":48},{"nctId":"NCT01136564","phase":"PHASE2","title":"Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease","status":"COMPLETED","sponsor":"Erling Bjerregaard Pedersen","startDate":"2010-07","conditions":"Chronic Kidney Disease","enrollment":30},{"nctId":"NCT00421733","phase":"PHASE2","title":"The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Diabetic Nephropathy, Chronic Kidney Disease","enrollment":281},{"nctId":"NCT00537979","phase":"PHASE4","title":"Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-09","conditions":"Secondary Hyperparathyroidism, Dialysis","enrollment":147},{"nctId":"NCT00091975","phase":"PHASE3","title":"Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-08","conditions":"Kidney Disease","enrollment":78},{"nctId":"NCT00646035","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-01","conditions":"End Stage Renal Disease","enrollment":75},{"nctId":"NCT00048438","phase":"PHASE3","title":"Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-02","conditions":"Renal Insufficiency, Chronic","enrollment":68},{"nctId":"NCT00048516","phase":"PHASE3","title":"Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-02","conditions":"Renal Insufficiency, Chronic","enrollment":68},{"nctId":"NCT00048451","phase":"PHASE3","title":"Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-02","conditions":"Renal Insufficiency, Chronic","enrollment":68}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"THROMBOSIS"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"BACTERAEMIA"},{"count":1,"reaction":"EPISTAXIS"},{"count":1,"reaction":"FULL BLOOD COUNT DECREASED"},{"count":1,"reaction":"LEUKOPENIA"},{"count":1,"reaction":"MOUTH HAEMORRHAGE"},{"count":1,"reaction":"PRURITUS"},{"count":1,"reaction":"PULMONARY EMBOLISM"},{"count":1,"reaction":"SKIN DISCOLOURATION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-358","Zemplar","paricalcitol"],"phase":"marketed","status":"active","brandName":"paricalcitol capsules","genericName":"paricalcitol capsules","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion. Used for Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis, Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 not on dialysis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}